Last reviewed · How we verify

Palmitoylethanolamide — Competitive Intelligence Brief

Palmitoylethanolamide (PALMIDROL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain.

phase 3 Cannabinoid receptor 2, Cannabinoid receptor 1, G-protein coupled receptor 55 Pain Small molecule Live · refreshed every 30 min

Target snapshot

Palmitoylethanolamide (PALMIDROL). Palmitoylethanolamide works by binding to the G-protein coupled receptor 55, which helps regulate inflammation and pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Palmitoylethanolamide TARGET PALMIDROL phase 3 Cannabinoid receptor 2, Cannabinoid receptor 1, G-protein coupled receptor 55

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Palmitoylethanolamide — Competitive Intelligence Brief. https://druglandscape.com/ci/palmidrol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing